Monday, October 07, 2024 11:29:49 PM
Investor082,
No, I’m saying a big pharma or a deep pocketed financier will ink a deal by then. It all depends on how big pharmas choose to play their cards with the threat of big money coming in to up the ante so to speak. If all pharmas play hardball after approval up until Flaskworks validation then I expect a financier to come in to get Flaskworks up and running with Sawston fitted out and the setup for Direct trial(s) started. Sooner or later the pharmas will be at the table to make a deal. You trying to time when to later than March makes sense if they are waiting on Flaskworks. I think Linda would like to speed things up a bit after approval but there could still be resistance and that, I believe, will be more costly for those resisting. Linda knows leverage!; ). Best wishes.
No, I’m saying a big pharma or a deep pocketed financier will ink a deal by then. It all depends on how big pharmas choose to play their cards with the threat of big money coming in to up the ante so to speak. If all pharmas play hardball after approval up until Flaskworks validation then I expect a financier to come in to get Flaskworks up and running with Sawston fitted out and the setup for Direct trial(s) started. Sooner or later the pharmas will be at the table to make a deal. You trying to time when to later than March makes sense if they are waiting on Flaskworks. I think Linda would like to speed things up a bit after approval but there could still be resistance and that, I believe, will be more costly for those resisting. Linda knows leverage!; ). Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
